<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03016624</url>
  </required_header>
  <id_info>
    <org_study_id>S-20150133</org_study_id>
    <nct_id>NCT03016624</nct_id>
  </id_info>
  <brief_title>Coronary Artery Healing and Bioresorbable Scaffold</brief_title>
  <acronym>HONEST</acronym>
  <official_title>Coronary Artery Healing Process After BiOresorbable Scaffold iN PatiEnts With Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare coronary healing after optical coherence tomography guided versus conventionally&#xD;
      angiography guided percutaneous coronary intervention with the Magmaris bioresorbable&#xD;
      scaffold.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:&#xD;
&#xD;
      Bioresorbable scaffolds (BRS) represent a novel approach during percutaneous coronary&#xD;
      intervention (PCI), which provides transient vessel support with drug-delivery capability&#xD;
      without the long-term limitations (very late stent thrombosis) of the metallic drug-eluting&#xD;
      stents. Patients with Non-ST-segment elevation myocardial infarction (NSTEMI) often feature&#xD;
      thrombus-rich lesions with large necrotic core, which may be associated with delayed arterial&#xD;
      healing and impaired stent-related outcomes. Besides clinical indication and underlying&#xD;
      plaque morphology, sufficient and potent strut coverage depends on several additional factors&#xD;
      (patient characteristics, stent type and procedural factors). Particularly, acute incomplete&#xD;
      stent apposition is a strong procedural risk factor for later deficient neointimal coverage.&#xD;
      Optical coherence tomography (OCT) is a high-resolution intravascular imaging modality, that&#xD;
      enables in-vivo evaluation of the immediate stenting result, and the vascular healing pattern&#xD;
      including strut coverage at follow-up.&#xD;
&#xD;
      AIM:&#xD;
&#xD;
      The objective of this study is to investigate if OCT-guided Magmaris BRS implantation in&#xD;
      patients with NSTEMI can improve the coronary arterial healing at 6 months compared to&#xD;
      routine angiographic guidance only. Further to investigate if the plaque composition/lipid&#xD;
      content will influence on the vascular healing.&#xD;
&#xD;
      METHOD:&#xD;
&#xD;
      The study is designed as a prospective, randomized trial. After pre-dilation, patients will&#xD;
      be randomly assigned to either: (1) OCT-guided PCI, or (2) angio-guided PCI with Magmaris BRS&#xD;
      implantation. In the OCT-guided group, OCT will be used for vessel and BRS sizing. After&#xD;
      Magmaris BRS implantation the result will be controlled with OCT and: 1) BRS under expansion&#xD;
      and/or, 2) strut malapposition and/or, 3) edge dissection- and/or 4) residual stenosis at the&#xD;
      distal and/or proximal reference segment(s) that may require further intervention. A final&#xD;
      OCT will be performed in case of re-intervention.&#xD;
&#xD;
      In the angio-guided group an OCT will be performed only after angiography final and&#xD;
      acceptable result.&#xD;
&#xD;
      A follow-up OCT will be performed after 6 months in all patients to assess the vascular&#xD;
      healing and a vasomotor test will be performed in half of the patients. After 12 months the&#xD;
      dynamic changes in vascular healing will be assessed in the first enrolled half of the&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Actual">August 29, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary artery healing score</measure>
    <time_frame>6 months</time_frame>
    <description>The primary endpoint is coronary artery healing score assessed by OCT Healing score is a weighted index that combines the following components: Uncovered scaffold struts, Uncovered &quot;jailed&quot; and acquired or persistent malapposed struts, Persistent mal apposition, Acquired mal apposition, Maximum neointimal growth and Accumulated extra stent lumen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coronary artery healing</measure>
    <time_frame>6 and 12 months.</time_frame>
    <description>Secondary endpoints are all individual components of coronary artery healing score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary artery healing</measure>
    <time_frame>6 months</time_frame>
    <description>Vasomotion at 6 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>OCT guided Magmaris implantation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous coronary intervention with Magmaris</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Angiography guided Magmaris implantation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous coronary intervention with Magmaris</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OCT guided PCI</intervention_name>
    <description>oct guided</description>
    <arm_group_label>OCT guided Magmaris implantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Angiography guided PCI</intervention_name>
    <description>angio guided</description>
    <arm_group_label>Angiography guided Magmaris implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with NSTEMI undergoing subacute PCI in native vessels and to be treated with&#xD;
             one or more drug eluting stents in coronary arteries due to a visually assessed&#xD;
             significant culprit lesion with &gt; 50% of coronary stenosis at the catheterization&#xD;
             laboratory in Odense.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients participating in other randomized stent studies.&#xD;
&#xD;
          -  Expected survival &lt; 1 year.&#xD;
&#xD;
          -  Allergy to aspirin, ticagrelor, clopidogrel and prasugrel.&#xD;
&#xD;
          -  Allergy to Sirolimus.&#xD;
&#xD;
          -  Aorta-ostial lesions (cannot be cleared with flush by OCT).&#xD;
&#xD;
          -  Serum creatinine &gt; 150 ug/L due to the required amount of X-ray contrast by OCT.&#xD;
&#xD;
          -  Twisted coronary vessels where the PCI-operator estimates that the introduction of an&#xD;
             OCT and / or NIRS catheter will not be possible or will be associated with increased&#xD;
             risk.&#xD;
&#xD;
          -  Lesion length &gt; 28 mm.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisette O Jensen, MD, DMSci, PhD, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <state>Region Of Southern Denmark</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 9, 2017</study_first_submitted>
  <study_first_submitted_qc>January 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2017</study_first_posted>
  <last_update_submitted>February 28, 2021</last_update_submitted>
  <last_update_submitted_qc>February 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Christian Oliver Fallesen</investigator_full_name>
    <investigator_title>MD, PhD student</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

